$25.63
-0.29-1.12%
At close: Jul 16, 5:00 PM EST
$25.63
N/A
After Hours: 4:00 PM EST
ACADIA Pharmaceuticals Inc Stock Guidance
ACADNASDAQ
ACADIA Pharmaceuticals (ACAD) last issued guidance on May 6, 2026 for fiscal year 2026. The company guided revenue in the range of $1.22B - $1.28B for the period.
Compared to prior guidance, ACADIA Pharmaceuticals maintained its revenue forecast from a prior range of $1.22B - $1.28B.
ACADIA Pharmaceuticals has issued 15 guidance updates between August 8, 2022 and May 6, 2026. During this period, the company raised its outlook 5 times and lowered it 3 times, providing investors with insight into management's evolving expectations.
Latest Guidance Date
May 6, 2026
Guidance Period
Full Year 2026
Revenue Guidance Range
$1.22B - $1.28B
ACADIA Pharmaceuticals Guidance History
Review all historical guidance issued by ACADIA Pharmaceuticals, including EPS and revenue forecasts across quarterly and annual periods.
Loading calendar...
FAQ
What is the most recent guidance for ACADIA Pharmaceuticals (ACAD)?
The most recent guidance for ACADIA Pharmaceuticals (ACAD) was reported on May 6, 2026 for the fiscal year 2026. ACADIA Pharmaceuticals forecasted revenue between $1.22B and $1.28B for the period.
What revenue range did ACADIA Pharmaceuticals (ACAD) guide for?
ACADIA Pharmaceuticals (ACAD) guided revenue in the range of $1.22B to $1.28B for the fiscal year 2026.
Did ACADIA Pharmaceuticals (ACAD) raise or lower guidance?
ACADIA Pharmaceuticals (ACAD) maintained its revenue guidance from a prior range of $1.22B - $1.28B to $1.22B - $1.28B for the fiscal year 2026.
When did ACADIA Pharmaceuticals (ACAD) last issue guidance?
ACADIA Pharmaceuticals (ACAD) last issued guidance on May 6, 2026 for the fiscal year 2026.
